Complix Overview

  • Year Founded
  • 2008

Year Founded

  • Status
  • Private

  • Employees
  • 11

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 12

Complix General Information

Description

Operator of a biopharmaceutical company intended to target intractable or challenging disease targets. The company is developing a transformative pipeline of alpha body therapeutics primarily addressing intracellular disease targets that play an important role in cancer, autoimmunity, and viral diseases, enabling patients to overcome the limitations of conventional antibodies and small molecules by combining the specific potency of biologics with the cell-penetrating capacity and stability of small molecules.

Contact Information

Website
www.complix.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • BioVille
  • Agoralaan building A-bis
  • 3590 Diepenbeek
  • Belgium
+32 09
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • BioVille
  • Agoralaan building A-bis
  • 3590 Diepenbeek
  • Belgium
+32 09

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Complix Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
14. Secondary Transaction - Private 01-Feb-2025 Completed Pre-Clinical Trials
13. Grant 07-Oct-2020 Completed Pre-Clinical Trials
12. Later Stage VC 01-Jan-2020 Completed Pre-Clinical Trials
11. Later Stage VC (Series D) 05-Aug-2019 Completed Pre-Clinical Trials
10. Secondary Transaction - Private 01-Feb-2019 Completed Pre-Clinical Trials
9. Grant 14-Dec-2017 Completed Pre-Clinical Trials
8. Later Stage VC (Series C) 30-Jun-2017 Completed Pre-Clinical Trials
7. Later Stage VC (Series B) 10-Apr-2015 Completed Pre-Clinical Trials
6. Later Stage VC (Series B) 27-May-2014 $5.14M $18.7M Completed Pre-Clinical Trials
5. Later Stage VC (Series B) 20-Aug-2013 $4.35M $13.6M Completed Pre-Clinical Trials
To view Complix’s complete valuation and funding history, request access »

Complix Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series D
Series C
Series B 15,934,290 $0.69 $0.69 1x $0.69 9.77%
Series A 11,323,198 $0.69 $0.69 1x $0.69 6.94%
To view Complix’s complete cap table history, request access »

Complix Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a biopharmaceutical company intended to target intractable or challenging disease targets. The company is de
Drug Discovery
Diepenbeek, Belgium
11 As of 2023

Henderson, NV
 

Antwerp, Belgium
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Complix Competitors (81)

One of Complix’s 81 competitors is Zura Bio, a Formerly VC-backed company based in Henderson, NV.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Zura Bio Formerly VC-backed Henderson, NV
Agomab Therapeutics Formerly VC-backed Antwerp, Belgium
Prothena Corporation Dublin, Ireland
CimCure Venture Capital-Backed Amsterdam, Netherlands
Vera Therapeutics Formerly VC-backed Brisbane, CA
You’re viewing 5 of 81 competitors. Get the full list »

Complix Patents

Complix Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2023203127-A1 Alphabody-based degrader molecules Inactive 20-Apr-2022
WO-2023170173-A1 Polypeptides capable of inhibiting sars-cov-2 viruses Inactive 08-Mar-2022
EP-4036117-A1 Mcl-1 binding alphabodies and uses thereof Inactive 27-Jan-2021
EP-4284833-A1 Mcl-1 binding alphabodies and uses thereof Inactive 27-Jan-2021
US-20240317807-A1 Mcl-1 binding alphabodies and uses thereof Inactive 27-Jan-2021 C07K14/00
To view Complix’s complete patent history, request access »

Complix Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Complix Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds
Vlaanderen verbeelding werkt Limited Partner
VLAIO Limited Partner Minority
Baekeland Fonds II Corporation Minority
Gimv PE/Buyout Minority
PMV (Belgium) Asset Manager Minority
You’re viewing 5 of 12 investors. Get the full list »

Complix FAQs

  • When was Complix founded?

    Complix was founded in 2008.

  • Where is Complix headquartered?

    Complix is headquartered in Diepenbeek, Belgium.

  • What is the size of Complix?

    Complix has 11 total employees.

  • What industry is Complix in?

    Complix’s primary industry is Drug Discovery.

  • Is Complix a private or public company?

    Complix is a Private company.

  • What is Complix’s current revenue?

    The current revenue for Complix is .

  • How much funding has Complix raised over time?

    Complix has raised $31.4M.

  • Who are Complix’s investors?

    Vlaanderen verbeelding werkt, VLAIO, Baekeland Fonds II, Gimv, and PMV (Belgium) are 5 of 12 investors who have invested in Complix.

  • Who are Complix’s competitors?

    Zura Bio, Agomab Therapeutics, Prothena, CimCure, and Vera Therapeutics are some of the 81 competitors of Complix.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process